# NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

Source: https://onco.cc/trials/nct06012695/  
OnCo record `nct06012695` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Temozolomide in advanced solid tumours, run by Novelwise Pharmaceutical Corporation, now recruiting.

## Summary

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma is a phase 1/2 interventional study registered as NCT06012695 by Novelwise Pharmaceutical Corporation, with 79 participants planned, started 2023-08-11 and due to reach its primary completion in 2028-05-30. Interventions recorded: NBM-BMX Capsule, Temozolomide and Standard radiotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06012695
- Phase: 1/2
- Setting: A Phase Ib/II, Open-label Study of NBM-BMX as Monotherapy or in Combination With Radiotherapy and Temozolomide in Subjects With Solid Tumors or Newly Diagnosed Glioblastoma
- Sponsor: Novelwise Pharmaceutical Corporation
- Enrolled: 79

## Sources

- ClinicalTrials.gov NCT06012695: https://clinicaltrials.gov/study/NCT06012695

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)

---
JSON: https://onco.cc/api/v1/entities/nct06012695.json